Developing Novel Conjugate HIV-1 Subunit Therapeutic Vaccines.
Abstract
Over the past several years, conjugate vaccines have met with much greater success and a number of these vaccines have received United States Food and Drug Administration (FDA) approval for use in adults and infants. Thus, it is the overall objective of this research project to assess the potential of an HIV-1 envelope glycoprotein (gp120) conjugate-based vaccine to induce high, long-lasting anti-HIV-1 envelope antibody titers with group specific neutralizing activity against primary and laboratory isolates of HIV-1.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 1996
- Accession Number
- ADB218771
Entities
People
- Tran C. Chanh
Organizations
- Texas Biomedical Research Institute